Oslo, Norway, 20 August 2019

Nordic Nanovector ASA (OSE: NANO) announces the appointment of Dr Lars Nieba as
Chief Technology Officer and a member of the executive management team. Dr Nieba
brings 20 years of leadership experience in the development of multiple
pharmaceutical product candidates and innovative technologies. His role at
Nordic Nanovector will be to oversee all Chemistry, Manufacturing and Controls
(CMC) strategic and operational aspects of Betalutin® and all other
pharmaceutical products developed by the company.

Dr Nieba will join Nordic Nanovector on 1 December 2019 from Bayer AG, where he
served as VP and Strategic Product Lead, responsible for driving Bayer's CMC
strategy related to CMC product development, product supply and life cycle
management of certain of its products (e.g. EYLEA®). He joined Bayer in 2016
following 13 years at F. Hoffmann-La Roche Ltd., at which he held leadership
roles in clinical supply planning, biologics technology and technical business
development biologics.

Dr Nieba gained a PhD from the Max-Planck-Institute for Biochemistry, München
and Institute for Biochemistry at the University of Zürich, and an Executive
MBA; University of St. Gallen, Switzerland. He holds dual Swiss/German
nationality and is a Swiss resident.

Eduardo Bravo, Nordic Nanovector's Chief Executive Officer, said, "Lars is an
important hire for Nordic Nanovector, bringing valuable complementary expertise
to the executive team. He will play a crucial role in refining and executing our
CMC strategy for Betalutin® in non-Hodgkin's lymphoma as well as for the other
assets in our emerging pipeline of targeted radioimmunotherapies. We are pleased
to welcome Lars to the team."

Lars Nieba commented: "I am delighted to be joining Nordic Nanovector. Betalutin
is a very exciting new treatment, since this novel targeted radioimmunotherapy
offers a clearly differentiated therapy option for patients with non-Hodgkin's
lymphoma. I look forward to using my knowledge and expertise to make an
important contribution to Nordic Nanovector's future success and to ensure that
we are well prepared for regulatory filings for Betalutin®, both in the USA and
Europe."

EYLEA® is a registered trademark of Regeneron Pharmaceuticals, Inc.

For further information, please contact:

IR enquiries

Malene Brondberg, VP Investor Relations and Corporate Communications

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 638 9571

Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain
marketing rights and to actively participate in the commercialisation of
Betalutin® in core markets. Further information can be found at
www.nordicnanovector.com

Forward-looking statements

This press release contains certain forward-looking statements. These statements
are based on management's current expectations and are subject to uncertainty
and changes in circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector's business, financial condition and results
of operations. The terms "anticipates", "assumes", "believes", "can", "could",
"estimates", "expects", "forecasts", "intends", "may", "might", "plans",
"should", "projects", "targets", "will", "would" or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector's
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector's product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector's potential market and
industry, Nordic Nanovector's freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Securities Trading Act.